TTR and amyloidosis: The second example refers to a therapy for transthyretin amyloidosis, in which CRISPR-Cas9 complexes packaged in lipid nanoparticles (which mainly condense in the liver) contribute to the reduction of a misfolded protein (NTLA-2001, NCT04601051).15